Department of Health and Human Services
National Institutes of Health
Toggle navigation
Search
Home
About the Clinical Center
Clinical Trials & You
Participate in a Study
Referring a Patient
How to Search
Contact Us
Search the Studies
Go Back
Searched Result
106 Studies found from all possible combinations of your search terms. Select a protocol that you wish to review.
Protocol Number
Title
Protocol Status
Min-Max Age
Institute
Keywords
001109-C
Defining the Natural History of Squamous Cell Carcinoma in Fanconi Anemia
Participants currently recruited/enrolled
8-125 Years
NCI
Carcinoma
001099-C
A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-Fusion Molecule, in Subjects with Unresectable, Locally Advanced, or Metastatic Solid Tumors that
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
001032-C
BAY 1895344 Plus Topoisomerase-1 (Top1) Inhibitors in Patients with Advanced Solid Tumors, Phase I Studies with Expansion Cohorts in Small Cell Lung Carcinoma (SCLC), Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) and Pancreatic Adenocarcinoma (
Recruitment has not started
18-125 Years
NCI
Carcinoma
001004-C
A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon Oncosignature (R) Status
Participants currently recruited/enrolled
18-120 Years
NCI
Carcinoma
000930-C
A Phase 1b/2 Study of HCW9218, a Bifunctional TGF-Beta Antagonist/IL-15 Protein Complex, for Advanced Pancreatic Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
000826-C
An Open Label, Randomised, Phase 2 Study to Evaluate the Safety and Efficacy of MTL-CEBPA Administered in Combination with Sorafenib or Sorafenib Alone, in TKI Naive Participants with Previously Treated Advanced Hepatocellular Carcinoma (HCC) and Hepatit
Recruitment has not started
18-125 Years
NCI
Carcinoma
000782-C
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors
Recruitment has not started
18-125 Years
NCI
Carcinoma
000666-C
A Phase I/II Study of Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)
Recruitment has not started
18-125 Years
NCI
Carcinoma
000596-C
Phase II Study of Olaparib in Subjects with Advanced Pancreatic Acinar Cell Carcinoma
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
000580-C
A Phase 1/2, Open Label Dose-Escalation and Expansion Trial of Nkt2152, an Orally Administered Hif2a Inhibitor, to Investigate Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity in Patients with Advanced Clear Cell Renal Cell Carcinoma
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
000520-C
Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG with or without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer
Recruitment has not started
18-125 Years
NCI
Carcinoma
000491-C
Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
000486-C
A Phase 1 Trial of the ATR Inhibitor BAY 1895344 in Combination with Cisplatin and with Cisplatin Plus Gemcitabine in Advanced Solid Tumors with an Emphasis on Urothelial Carcinoma
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
000473-C
A Randomized Phase II Study of Systemic Chemotherapy with or without HAI FUDR-Dexamethasone in Patients with Unresectable Intrahepatic Cholangiocarcinoma
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
000462-C
Phase 2, Open-label, Single-arm, Window of Opportunity Study of ASP-1929 Photoimmunotherapy with Fluorescence Imaging in Patients With Operable Primary or Recurrent Head and Neck or Cutaneous Squamous Cell Carcinoma
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
000354-C
Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
000317-C
A Phase II, Open-Label Trial of PT-112 in Subjects with Thymoma and Thymic Carcinoma
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
000302-C
A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
000254-C
A Phase II Trial of the Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP)
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
000237-C
Phase II Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis from Colorectal, Appendiceal, Small Bowel, Gastric, Ovarian, or Other Gynecologic Primary Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
000080-C
18F-DCFPyL PET/CT in Hepatocellular Carcinoma
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
000077-DC
Collection of Clinical Data and Specimens for Research on Head and Neck and Communication Disorders
Participants currently recruited/enrolled
2-125 Years
NIDCD
Carcinoma
22-C-0005
Phase I Dose Escalation and Expansion Study of Tazemetostat in Combination with Topotecan and Pembrolizumab in Recurrent Small Cell Lung Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
22-C-0004
A Phase II Study of Bevacizumab, Erlotinib and Atezolizumab in Subjects with Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Associated or Sporadic Papillary Renal Cell Cancer
Participants currently recruited/enrolled
12-125 Years
NCI
Carcinoma
21-DC-0002
Phase III Interventional Study using Atorvastatin to Reduce Cisplatin-Induced Hearing Loss among Individuals with Head and Neck Cancer
Recruitment has not started
18-125 Years
NIDCD
Carcinoma
21-C-0030
Phase I Study of GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Hepatocellular Carcinoma (HCC)
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
21-C-0023
A Phase I Study of Pomalidomide and Nivolumab in Patients with Virus-Associated Malignancies With or Without HIV
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
21-C-0012
Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis from Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
20-D-0131
Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sj(SqrRoot)(Delta)gren's Syndrome; a Phase Ib-IIa Placebo-controlled Clinical Trial and Associated Mechanistic Studies
Participants currently recruited/enrolled
18-75 Years
NIDCR
Tongue
20-D-0094
Transmissibility and Viral Load of SARS-CoV-2 Through Oral Secretions
Completed Study; data analyses ongoing
18-125 Years
NIDCR
Tongue
20-CC-0039
A Feasibility Study to Evaluate the Combination of Electromagnetic Tracking and Optical Imaging with Indocyanine Green (ICG) for Hepatic Biopsies
Enrolling by Invitation
18-125 Years
CC
Carcinoma
20-C-0152
Phase II Study of combination of Trametinib (MEK inhibitor) and Hydroxychloroquine (HCQ) (autophagy inhibitor) in Patients with KRAS Mutation Refractory Bile Tract Carcinoma (BTC).
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
20-C-0149
Phase II Trial of Olaparib (LYNPARZA) plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas that Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
20-C-0142
A Phase II Study of Bintrafusp alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects with Urothelial Carcinoma
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
20-C-0098
A Phase 1/2, Open Label, Dose-Escalation, Safety and Tolerability Study of NC410 in Subjects with Advanced or Metastatic Solid Tumors
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
20-C-0097
A Phase II, Open-Label Trial of Bintrafusp Alfa (M7824) in Subjects with Thymoma and Thymic Carcinoma
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
20-C-0024
A Sequential Window of Opportunity Trial of Anti-PD-L1/TGF-beta trap (M7824 ) Alone and in Combination with TriAd Vaccine, and N-803 for Resectable Head and Neck Squamous Cell Carcinoma not Associated with Human Papillomavirus Infection.
No longer recruiting/follow-up only
18-125 Years
NCI
Carcinoma
20-C-0022
Phase II trial of VB-111 in Combination with Nivolumab in Patients with Metastatic Colorectal Cancer (mCRC)
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
20-C-0013
Phase I/II Trial of PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers
No longer recruiting/follow-up only
18-125 Years
NCI
Carcinoma
20-C-0012
A Phase I Study of Bintrafusp alfa (M7824) and NHS-IL12 (M9241) Alone and in Combination with Stereotactic Body Radiation Therapy (SBRT) in Adults with Metastatic Non-Prostate Genitourinary Malignancies
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
20-C-0009
Randomized Phase II Trial of Topotecan Plus M6620 (VX-970) vs. Topotecan Alone in Patients with Relapsed Small-Cell Lung Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
20-C-0006
A National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer (PLC)
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
19-C-0137
A Phase II Study of Ipilimumab, Cabozantinib, and NIvolumab in Rare Genitourinary Cancers (ICONIC)
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
19-C-0134
A Phase 1/1b Study of Enhancement of Immune Reconstitution and Vaccine Responses with Administration of Recombinant Human IL-7-hyFc (NT-I7) in Older Subjects Following Chemotherapy
Participants currently recruited/enrolled
60-125 Years
NCI
Carcinoma
19-C-0129
A Phase II Study of Intraperitoneal and Intravenous Paclitaxel Chemotherapy with Oral Capecitabine for Gastric Adenocarcinoma with Peritoneal Carcinomatosis
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
19-C-0094
A Phase II Study of Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects with Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinoma (BTC)
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
19-C-0041
Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
19-C-0039
Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
19-C-0033
Phase II Study of Nivolumab (anti-PD1), Tadalafil and Oral Vancomycin in Patients with Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer from Colorectal or Pancreatic Cancers
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
19-C-0023
A Phase II Study of Olaparib (AZD2281) in Patients with Metastatic/Advanced Urothelial Carcinoma and other genitourinary tumors with DNA-Repair Defects
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
19-C-0016
Natural History and Biospecimen Acquisition Study for Children and Adults with Rare Solid Tumors
Participants currently recruited/enrolled
0-125 Years
NCI
Carcinoma
18-I-0101
Sample Collection From Healthy Volunteers for Assay Optimization
Participants currently recruited/enrolled
18-125 Years
NIAID
Tongue
18-H-0012
A Phase I Study of HERV-E TCR Transduced Autologous T Cells in Patients with Metastatic Clear Cell Renal Cell Carcinoma
Participants currently recruited/enrolled
18-75 Years
NHLBI
Carcinoma
18-DK-0091
Long-Term Follow-Up Of Subjects With CHC Who Achieved A Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents
Participants currently recruited/enrolled
18-125 Years
NIDDK
Carcinoma
18-C-0147
Phase 1 with Expansion Cohorts in a Study of NEO-201 In Adults with Chemo-Resistant Solid Tumors
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
18-C-0138
An Open-Label Phase 2 Study to Evaluate PT2977 for the Treatment of Von Hippel-Lindau Disease-Associated Renal Cell Carcinoma.
No longer recruiting/follow-up only
18-125 Years
NCI
Carcinoma
18-C-0110
Safety Run-In and Phase II Trial of M7824 and Topotecan or Temozolomide in Relapsed Small Cell Cancers
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
18-C-0062
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Completed Study; data analyses ongoing
2-30 Years
NCI
Carcinoma
18-C-0034
A Phase 2 Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
18-C-0024
A Single-Arm Phase II Study of Hepatic Artery Infusion Pump Chemotherapy with Floxuridine and Dexamethasone in Combination with Systemic Chemotherapy for Patients with Colorectal Cancer Metastatic to the Liver
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
18-C-0008
Phase III Randomized Adjuvant study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) versus Observation
No longer recruiting/follow-up only
18-125 Years
NCI
Carcinoma
17-DC-0138
Observational Study of Hearing Loss and the Effects of Statin Drugs in Head and Neck Squamous Cell Carcinoma Patients Treated with Cisplatin Chemoradiation
Completed Study; data analyses ongoing
18-125 Years
NIDCD
Carcinoma
17-C-0157
A Phase I Single-Arm Study of the Combination of Durvalumab (MEDI4736) and Vicineum (oportuzumab monatox, VB4-845) in Subjects with High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated with Bacillus Calmette-Gu(SqrRoot)(Copyright)rin (BCG)
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
17-C-0140
Phase I/II Evaluation of Oral Decitabine/Tetrahydrouridine as Epigenetic Priming for Pembrolizumab Immune Checkpoint Blockade in Inoperable Locally Advanced or Metastatic Non-Small Cell Lung Cancers, Esophageal Carcinomas, or Pleural Mesotheliomas
Completed Study; data analyses ongoing
18-99 Years
NCI
Carcinoma
17-C-0117
A Phase 1/2a, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of PEN-866 in Advanced Solid Malignancies
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
17-C-0092
A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination with Immune Checkpoint Inhibition in Refractory Colorectal Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
17-C-0086
An Open-label Phase 2 Study to Evaluate PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma
No longer recruiting/follow-up only
18-125 Years
NCI
Carcinoma
17-C-0066
A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma after Progression on Platinum-Based Chemotherapy
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
17-C-0011
Phase 1 Study of Intraperitoneal Infusion of Autologous Monocytes with Sylatron (Peginterferon alfa-2b) and Actimmune (Interferon gamma-1b) in Women with Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
16-CC-0162
Longitudinal Changes in the Oral and Gut Microbiome of Individuals with Alcohol Dependence
Completed Study; data analyses ongoing
18-125 Years
CC
Tongue
16-C-0154
A Phase I/II Trial of T Cell Receptor Gene Therapy Targeting HPV-16 E7 for HPV-Associated Cancers
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
16-C-0135
A Pilot Study of Combined Immune Checkpoint Inhibition in combination with Ablative Therapies in Subjects with Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
No longer recruiting/follow-up only
18-125 Years
NCI
Carcinoma
16-C-0128
A Phase I/II Study of Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination with Nab-Paclitaxel in Participants with Previously Treated Metastatic and/ or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
16-C-0121
A Pilot Clinical Trial of Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
16-C-0107
A Phase I/II Trial of EP0057, a Nanoparticle Camptothecin with Olaparib in Patients with Relapsed/Refractory Small Cell Lung, Bladder and Prostate Cancers
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
15-M-0066
Influence on Plasticity of Brain Temperature
Participants currently recruited/enrolled
18-50 Years
NIMH
Tongue
15-D-0051
Characterization of Diseases with Salivary Gland Involvement
Participants currently recruited/enrolled
4-125 Years
NIDCR
Tongue
15-C-0160
A Phase I Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination with Ipilimumab (CaboNivoIpi) in Patients with Advanced/Metastatic Urothelial Carcinoma and other Genitourinary Tumors
No longer recruiting/follow-up only
18-125 Years
NCI
Carcinoma
15-C-0157
Phase I/II Trial of Vandetanib in Combination with Metformin in Subjects with HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
15-C-0150
A Phase I/II Trial of Topotecan with VX-970 (M6620), an ATR Kinase Inhibitor in Small Cell Cancers
No longer recruiting/follow-up only
18-125 Years
NCI
Carcinoma
15-C-0099
A Phase 1, Open-Label, Dose-Escalation Study of SNX-5422 and Everolimus in Subjects with Neuroendocrine Tumors
Completed Study; data analyses ongoing
18-100 Years
NCI
Carcinoma
15-AR-0144
Studies of Dermatologic Diseases-Biospecimen Acquisition Protocol
Participants currently recruited/enrolled
2-125 Years
NIAMS
Carcinoma
14-HG-0055
Study on Moebius Syndrome and Other Congenital Facial Weakness Disorders
Completed Study; data analyses ongoing
2-80 Years
NHGRI
Tongue
14-C-0104
A Phase II Study Using Autologous Young Tumor-Infiltrating Lymphocytes Derived from Patients with Non-Small Cell Lung Cancer Following Non-Myeloablative Lymphocyte Depleting Preparative Regimen
Participants currently recruited/enrolled
18-70 Years
NCI
Carcinoma
14-C-0037
A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
14-C-0015
Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
13-C-0118
A Phase I/II Trial of TRC102 (methoxyamine HCl) in Combination with Temozolomide in Patients with Relapsed Solid Tumors and Lymphomas
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
12-C-0205
A Phase II Study of Cabozantinib (XL184) in Patients With Advanced/Metastatic Urothelial Carcinoma
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
12-C-0178
Longitudinal Assessment and Natural History Study of Children and Adults with MEN2A or MEN2B with or without Medullary Thyroid Carcinoma
Participants currently recruited/enrolled
0-125 Years
NCI
Carcinoma
12-C-0118
A Phase II Study of Sunitinib in Patients with Advanced Relapsed or Refractory Thymoma or Thymic Carcinoma with at Least One Prior Line of Platinum-Based Systemic Chemotherapy
No longer recruiting/follow-up only
18-100 Years
NCI
Carcinoma
11-CC-0152
The Natural History of Liver Disease in a Cohort of Participants with Hepatitis B and/or Hepatitis C with or without HIV Infection
Completed Study; data analyses ongoing
18-99 Years
CC
Carcinoma
11-C-0140
A Phase I Study of Gemcitabine, Carboplatin and Lenalidomide (GCL) for Treatment of Patients with Advanced/Metastatic Urothelial Carcinoma (UC) and Other Solid Tumors
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
11-C-0096
Pilot Trial of Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
No longer recruiting/follow-up only
18-125 Years
NCI
Carcinoma
10-C-0166
A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphodepleting Regimen in Metastatic Cancers Plus the Administration of Pembrolizumab
Participants currently recruited/enrolled
18-72 Years
NCI
Carcinoma
10-C-0114
A Phase II Study of Bevacizumab and Erlotinib in Subjects with Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
09-C-0161
Follow-Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies
Enrolling by Invitation
18-125 Years
NCI
Carcinoma
08-I-0184
Studies in the Pathogenesis of Anaphylaxis
Participants currently recruited/enrolled
13-75 Years
NIAID
Tongue
08-H-0186
Safety and the Anti- Tumor Effects of Escalating Doses of Adoptively Infused Ex Vivo Expanded Autologous Natural Killer (NK) Cells Against Metastatic Cancers or Hematological Malignancies Sensitized to NK-TRAIL Cytotoxicity with Bortezomib
Completed Study; data analyses ongoing
18-70 Years
NHLBI
Carcinoma
07-C-0121
Phase 2 Study of the C-Met RTK Inhibitor Foretinib (Formerly GSK 1363089) in Subjects with Papillary Renal Cell Carcinoma (PRC)
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
05-CC-0091
Electromagnetic Tracking of Devices During Interventional Procedures
Enrolling by Invitation
18-125 Years
CC
Carcinoma
02-C-0313
Cancer Risk in Xeroderma Pigmentosum Heterozygotes
Participants currently recruited/enrolled
0-99 Years
NCI
Carcinoma
02-C-0064
Collection of Peripheral Blood and/or Urine From Patients Undergoing Radiation Therapy
Enrolling by Invitation
18-125 Years
NCI
Carcinoma
00-C-0078
Collection of Blood, Fluid, Bone Marrow, Tumor, or Tissue Samples from Patients with Cancer or Normal Volunteers
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
94-E-0165
Studies in the Natural History and Pathogenesis of Childhood-Onset and Adult-Onset Idiopathic Inflammatory Myopathies
Participants currently recruited/enrolled
2-100 Years
NIEHS
Tongue
89-C-0086
Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders
Participants currently recruited/enrolled
2-125 Years
NCI
Carcinoma
79-C-0111
The Treatment of Stage I and II Carcinoma of the Breast with Mastectomy and Axillary Dissection vs. Excisional Biopsy Axillary Dissection, and Definitive Irradiation
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma